Products for Research Use Only
RegisterLogin

KCL-286

CAT: 0804-HY-111573-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-111573-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
KCL-286 (C286) is an orally active and brain-penetrant retinoic acid receptor (RAR) β2 agonist (EC50 = 1.9 nM) . KCL-286 targets RARβ2 with good selectivity over RAR α (EC50 = 26 nM) and RAR γ (EC50 = 11 nM) . KCL-286 activates RARβ2 in the injured neurons. KCL-286 induces axonal regeneration of both spinal and sensory nerves through the inhibitory environment of the CNS, modulates neuroinflammation and extracellular matrix molecules. KCL-286 can modulate the expression of CSPGs by neuronal secretion of decorin which promotes myelination and aids axonal growth. KCL-286 can be studied in research for area such as spinal cord injury and traumatic nerve injury[1][3].
CAS Number
1952276-71-9
Product Name Alternative
C286
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
RAR/RXR
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Inflammation/Immunology; Neurological Disease; Others
Assay Protocol
https://www.medchemexpress.com/anticancer-agent-168.html
Purity
98.93
Solubility
DMSO : 6.25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC1=CC=C(C)C2=C1OC(C3=NC(C4=CC=C(C(O)=O)C=C4)=NO3)=C2
Molecular Formula
C19H14N2O4
Molecular Weight
334.33
Precautions
H302, H312, H332
References & Citations
[1]Goncalves MB, et al. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. Br J Clin Pharmacol. 2023 Jul 15..|[2]Goncalves, M. B., (2024) . C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair. Frontiers in molecular neuroscience, 17, 1411384. |[3]Borthwick, A. D., et al., (2020) . Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review. Bioorganic & medicinal chemistry, 28 (20), 115664.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-15050KCL-440
HY-175660KCL-HO-1i
HY-115489GGTI-286
HY-15571AVCH-286
HY-175334-01DHC-286
HY-175313Antibacterial agent 286
HY-P5363PAP 248-286
HY-117935GGTI-286 (hydrochloride)
HY-W1008867CRBN ligand-286
HY-P1843Glycoprotein (276-286)

Alternative Products

CatalogName
T78575-01KCL-286
90345002M KCl
PCR-262-10MlKCl Buffer
ST345-250ml3M KCl
ARC0386KCL-22
MBS5783919KCL-440
GTR19273111-01KCL-HO-1i
T29100-01VCH-286
262826-01BML-286
MBS130420-01HTI-286

Popular Products